Transdermal PTEN mRNA Delivery via HA-LNPs for Melanoma Ther
2026-05-29
Transdermal Delivery of PTEN mRNA with Hyaluronated Lipid Nanoparticles: Advancing Melanoma Immunotherapy
Study Background and Research Question
Melanoma remains one of the most aggressive and treatment-resistant forms of skin cancer, characterized by late diagnosis, high metastatic potential, and suboptimal response rates to existing therapies. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 antibodies, have improved clinical outcomes for some patients, yet resistance—often mediated by tumor-intrinsic factors—remains a major challenge. Loss or mutation of the tumor suppressor gene PTEN is a recurrent event in melanoma and other cancers, contributing to unchecked cellular proliferation, PI3K/Akt signaling pathway activation, and immune evasion by impairing T cell infiltration and cytotoxicity. Restoring PTEN function has emerged as a promising strategy to counteract these mechanisms, but traditional gene delivery methods face significant drawbacks, including risk of genomic integration, immunogenicity, and inefficient cytosolic delivery. The reference study (Kim et al., J. Control. Release 2026) posed the central question: Can a non-invasive, targeted, and biocompatible delivery system for PTEN mRNA effectively restore tumor suppressor activity and overcome immune resistance in melanoma?Key Innovation from the Reference Study
The study by Kim et al. introduces a novel platform: hyaluronate-conjugated lipid nanoparticles (HA-LNPs) designed for transdermal mRNA delivery. By integrating hyaluronate (HA) directly into the lipid bilayer using HA-dimyristoyl glycerol (HA-DMG), the resulting nanoparticles achieve several objectives:- Elimination of poly(ethylene glycol) (PEG) from the formulation, addressing concerns of PEG-induced immunogenicity and anaphylaxis.
- Stable surface presentation of HA moieties, promoting CD44-mediated targeting and efficient skin/tumor penetration.
- Enhanced encapsulation and protection of large mRNA payloads, specifically PTEN mRNA.
Methods and Experimental Design Insights
Kim et al. developed HA-LNPs by self-assembly of lipid mixtures containing HA-DMG, which integrates uniformly into the nanoparticle structure. The use of HA as both a stabilizing and targeting ligand eliminates the need for post-formulation surface modifications. PTEN mRNA was encapsulated during the nanoparticle assembly process, resulting in uniformly sized particles suitable for skin application. In vitro experiments assessed the uptake of PTEN mRNA-loaded HA-LNPs (PTEN mRNA@HA-LNP) by CD44-expressing melanoma cells, restoration of PTEN expression, induction of immunogenic cell death (ICD), and effects on cell viability. In vivo, the transdermal application of these nanoparticles was evaluated in a melanoma mouse model, with analyses focused on skin/tumor penetration, restoration of PTEN function, tumor growth inhibition, immune activation, and systemic toxicity.Protocol Parameters
- HA-LNP formulation: Incorporate HA-DMG into the lipid mixture for self-assembly; optimize HA content for maximal CD44 targeting and particle stability.
- mRNA encapsulation: Encapsulate full-length PTEN mRNA during nanoparticle assembly; confirm encapsulation efficiency and mRNA integrity.
- Transdermal application: Apply HA-LNP suspension topically to the tumor-bearing skin region in animal models; monitor for penetration, distribution, and therapeutic efficacy.
- Immune and tumor response monitoring: Assess PTEN protein restoration, ICD markers (e.g., calreticulin exposure), T cell infiltration, and tumor burden over time.
Core Findings and Why They Matter
The study demonstrated that PTEN mRNA@HA-LNPs:- Efficiently restored PTEN expression in melanoma cells in vitro, reversing the PI3K/Akt-driven survival and proliferation phenotype.
- Induced immunogenic cell death, as evidenced by upregulation of ICD markers and reduced melanoma cell viability.
- Achieved deep skin and tumor penetration following topical application in vivo, with significant restoration of PTEN protein in tumor tissue.
- Suppressed tumor growth and improved immune activation, with increased T cell infiltration and minimal systemic toxicity (Kim et al., 2026).